Non Animal Testing, Alternative Test Methods, In Vitro Toxicology, IIVS | Industries Tobacco
63
archive,tax-industry,term-tobacco,term-63,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Archive

Tobacco Companies Embracing In Vitro Toxicology

October 29, 2018
The tobacco industry is facing increased testing requirements for e-cigarettes and other tobacco products that entered the market after Feb. 15, 2007.  Companies hope in vitro tests that use human lung cells or tissues will be sufficient to show that their new tobacco products, including e-cigarettes, significantly reduce harm and disease and benefit the population as a whole when compared with traditional cigarettes.  Several of them are working with independent, third-party laboratories, including the Institute for In Vitro Sciences (IIVS),...

Webinar: Precision-cut Lung Slices

October 5, 2018
Dr. Holger Behrsing, Principal Scientist with IIVS, recently presented "Precision-cut Lung Slices (PCLS)" for the 2018 PETA International Science Consortium webinar series on non-animal inhalation testing methods. ...

Registration Now Open for Practical Methods 2019

August 27, 2018
IIVS is excited to announce that registration is now open for our 2019 Practical Methods for In Vitro Toxicology Workshop. Space is limited so please book as soon as possible to guarantee your spot. ...

Abstract Deadline Extended for EUSAAT 2018

June 21, 2018
The 21st European Congress on Alternatives to Animal Testing & 18th Annual Congress of EUSAAT (European Society for Alternatives to Animal Testing) will take place in Linz, Austria, 23-26 September.  Submission deadlines for both oral and poster presentations have been extended to July 6. Erin Hill and Rodger Curren from IIVS are both speaking at the event. Learn more about the meeting, including the scientific program, invited speakers, and how to register.  ...

Next-Generation Tobacco and Nicotine Products: Substantiating Harm Reduction and Supporting Tobacco Regulatory Science

June 21, 2018
A framework for the assessment of novel next-generation tobacco and nicotine products with the potential to reduce health risks compared with cigarettes should integrate scientific studies incorporating nonclinical, clinical, and population studies approaches.  These products should have lower emissions and exhibit reduced biological effects compared with those of cigarettes, ideally approaching those of smoking cessation.  The products should also be acceptable cigarette alternatives for current smokers, while not appealing to nonsmokers or former smokers.  Validating harm reduction and promoting regulatory acceptance...

Characterization of a Vitrocell VC1 Using Nicotine Dosimetry: An Essential Component Toward Standardized In Vitro Aerosol Exposure of Tobacco and Next Generation Nicotine Delivery Products

June 21, 2018
The U.S. Food and Drug Administration has regulatory authority over tobacco products, including conventional cigarettes and next generation products (NGPs) such as e-cigarettes and tobacco heating products (THPs).  There is a desire by the industry, regulators and animal protection organizations to incorporate non-animal test methods for tobacco product and NGP assessment.  When assessing respiratory effects in vitro, reliable exposure systems that deliver aerosols to cellular/tissue cultures (such as human reconstructed airways or lung slices) at the air–liquid interface are needed.  Using nicotine dosimetry, we report the...

Abstract Deadline Extended for ESTIV 2018

June 18, 2018
The 20th International Congress on In Vitro Toxicology (ESTIV2018) happening in Berlin, 15-18 October, has extended their abstract submission deadline to July 1.  Several grants and bursaries are also still open to applicants until July 1, including the PETA International Science Consortium early-career scientist award. Learn more about the meeting, including the scientific program, invited speakers, and how to register.  ...

Holger Behrsing, PhD, Participates in Round Table Discussion on Non-Animal Approaches for Inhalation Toxicology

June 14, 2018
Holger Behrsing, PhD, was recently invited to participate in an expert round table discussion convened on the development and implementation of 21st century non-animal approaches to assess the toxicity of inhaled substances.  The discussion included perspectives from government, industry, nonprofit, and academic sectors on the advantages and challenges of using these approaches, ongoing efforts, and steps needed to gain widespread use and acceptance of these approaches. A transcript of the discussion has just been published in Applied In Vitro Toxicology, Vol....

New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-Cigarettes

April 12, 2018
IIVS, in collaboration with Philip Morris International, recently presented data highlighting the predictive capability of in vitro assays in determining human response to non-burn tobacco products. Moreover, a ring trial of 6 independent laboratories has generated evidence that key events involved in human disease caused by nicotine-based products can be replicated using non-animal models. These results may increase interest in the use of alternative testing strategies for research and development and, eventually, regulatory acceptance.  Read article.  ...

Human In Vitro Models for Respiratory Toxicology: Evaluation of Goblet Cell Hyperplasia, Mucus Production, and Ciliary Beating Assays

March 28, 2018
Robust non-animal models and assays for pulmonary toxicology are required to make competent product development and risk assessments for new materials requiring toxicity testing. Three in vitro assays (goblet cell hyperplasia [GCH], ciliary beat frequency [CBF], and MUC5AC quantitation) were evaluated for performance and reproducibility. To assess these assays, 6 laboratories contributed data using a common protocol utilizing IL-13 as an inducer of adverse mucociliary-relevant tissue changes. MatTek EpiAirway™ and Epithelix MucilAir™ 3D tissue models were used to evaluate endpoints...